All In Biotech

Drug Trial Radar · NCT01155310

Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

An International Phase III Randomised Trial Comparing in Severe Exacerbations of Chronic Obstructive Pulmonary Disease the Efficacy of Helium/Oxygen Versus Air/Oxygen Administered During Spontaneous Breathing and Intermittent Non-Invasive Ventilation.

Last checked: Nov 19, 2026Latest source record: Oct 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 446 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

446

Actual

Start

May 2010

Primary completion

Oct 2013

Study completion Jun 2014

Sponsor

Sponsor type
Industry
First posted
Jul 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of Helium/Oxygen (He/O2) 78%/22% compared to a conventional Air/O2 mixture in reducing endotracheal intubation rate and mortality in patients with severe hypercapnic exacerbations of Chronic Obstructive Pulmonary Disease (COPD) during their index Intensive/Intermediate Care Unit (ICU) stay.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Helium/Oxygen 78%/22%Drug

    The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices. Patients will then receive the Air/Oxygen mixture with usual devices.

  • Air/OxygenDrug

    The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices. Patients will then receive the Air/Oxygen mixture with usual devices.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of NIV failureTime frame: 10 days (average)

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Les Cliniques Universitaires UCL Mont Godinne

    Yvoir, Belgium

  • Centre Hospitalier Universitaire Angers

    Angers, France

  • Centre Hospitalier Universitaire Pellegrin-Tripode

    Bordeaux, France

  • Hôpitaux de Chartes

    Chartres, France

  • CHU Clermont-Ferrand - Hôpital ESTAING

    Clermont-Ferrand, France

  • Hôpital Henri Mondor

    Créteil, France

  • CHU NICE - Hopital Pasteur

    Nice, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Européen Georges Pompidou

    Paris, France

  • Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer - Hopital Sainte Musse

    Toulon, France

  • Azienda Ospedaliera Univeritaria Careggi

    Florence, Italy

  • Hôpitaux Universitaires de Genève

    Geneva, Switzerland

  • Hôpital Abderrahmen Mami

    Aryanah, Tunisia

  • Centre Hospitalier Universitaire Fattouma Bourguiba

    Monastir, Tunisia

  • University Hospital of North Tees

    Stockton-on-Tees, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.